Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03392324 · ClinicalTrials.gov registry record · NA
PRIMA US-Feasibility Study in Atrophic Dry AMD
A NA study of Dry Age-Related Macular Degeneration, sponsored by Science Corporation.
- Active
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT03392324: Active NA study of Dry Age-Related Macular Degeneration, sponsored by Science Corporation.
NCT03392324 is a NA study of Dry Age-Related Macular Degeneration that is active but no longer recruiting, run by Science Corporation. The registered enrollment target is 5 participants, below the 83-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03392324, a NA study of Dry Age-Related Macular Degeneration, is active but no longer recruiting, sponsored by Science Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
Primary Outcome
Near Visual acuity measured by FrACT
Conditions Studied
Interventions
- DEVICE PRIMA
Study Locations (3)
California
- Byers Eye Institute-Stanford University - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
Pennsylvania
- UPMC Eye Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT03392324 still lists
NCT03392324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 83-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Dry Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which PRIMA is the first listed.
NCT03392324 reports a single indexed study location in California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03392324 about?
NCT03392324 is a clinical study titled "PRIMA US-Feasibility Study in Atrophic Dry AMD". In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
What is the current status of trial NCT03392324?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2018-04-26. Estimated completion is 2025-12.
What conditions does trial NCT03392324 study?
This clinical trial studies the following conditions: Dry Age-Related Macular Degeneration.
What interventions are being tested in trial NCT03392324?
The interventions under investigation include: PRIMA (DEVICE).
Who is sponsoring clinical trial NCT03392324?
This trial is sponsored by Science Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03392324 being conducted?
This trial has 3 study locations across California, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
ACTIVE NOT RECRUITING · NA
-
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
COMPLETED · NA
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI